ENTERA BIO LTD. (ENTX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 8.81M USD | Research and Development Expense |
| Revenue | 0.00 USD | |
| Stock-based compensation | 2.93M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -14.40M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.81M | $0.00 | $2.93M | $-14.40M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $7.13M | $0.00 | $2.82M | $-12.51M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $6.00M | $42.00K | $2.75M | $-11.53M | (m) | 14295.24% | 6547.62% | (m) | (m) |
| 2025-09-30 | $5.49M | $124.00K | $2.61M | $-10.82M | (m) | 4425.00% | 2101.61% | (m) | (m) |
| 2025-06-30 | $5.32M | $166.00K | $2.61M | $-10.59M | (m) | 3205.42% | 1570.48% | (m) | (m) |
| 2025-03-31 | $4.89M | $223.00K | $2.70M | $-10.09M | (m) | 2191.48% | 1208.97% | (m) | (m) |
| 2024-12-31 | $4.50M | $181.00K | $2.56M | $-9.59M | (m) | 2485.64% | 1412.15% | (m) | (m) |
| 2024-09-30 | $4.30M | $99.00K | $2.31M | $-9.21M | (m) | 4341.41% | 2331.31% | (m) | (m) |
| 2024-06-30 | $4.19M | $57.00K | $1.76M | $-8.58M | (m) | 7352.63% | 3092.98% | (m) | (m) |
| 2024-03-31 | $4.31M | (m) | $1.64M | $-8.74M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $4.51M | $0.00 | $1.69M | $-8.89M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $4.86M | $14.00K | $1.85M | $-10.00M | (m) | 34721.43% | 13200.00% | (m) | (m) |
| 2023-06-30 | $4.90M | $22.00K | $1.57M | $-10.47M | (m) | 22290.91% | 7159.09% | (m) | (m) |
| 2023-03-31 | $5.09M | $66.00K | $1.80M | $-11.39M | (m) | 7710.61% | 2725.76% | (m) | (m) |
| 2022-12-31 | $5.85M | $134.00K | $2.25M | $-13.02M | (m) | 4364.18% | 1676.87% | (m) | (m) |
| 2022-09-30 | $7.15M | $285.00K | $2.14M | $-14.04M | (m) | 2507.37% | 750.18% | (m) | (m) |
| 2022-06-30 | $7.50M | $417.00K | $2.66M | $-14.39M | (m) | 1799.52% | 636.93% | (m) | (m) |
| 2022-03-31 | $7.34M | $482.00K | $2.50M | $-13.71M | (m) | 1522.20% | 518.26% | (m) | (m) |
| 2021-12-31 | $6.77M | $571.00K | $1.86M | $-12.22M | (m) | 1185.81% | 325.92% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $6.38M | $365.00K | $901.00K | $-11.17M | (m) | 1748.49% | 246.85% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |